Impromen

Bromperidol, the active ingredient in Impromen, is a butyrophenone antipsychotic presented as an oral dosage form for oral use. It treats schizophrenia and acute psychotic disorders in adults. It is approved in the European Union for these indications and is available only by prescription.

GNH USA supplies Impromen as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to Good Distribution Practice, ensures product integrity during transport, and provides regulatory documentation to support import requirements.

Bromperidol is a butyrophenone antipsychotic that modulates dopaminergic pathways in psychotic disorders.

Schizophrenia: reduces positive and negative symptoms in adult patients. Acute psychotic disorders: helps control acute agitation and psychotic symptoms.

Bromperidol may cause a range of adverse reactions. Patients should be monitored for both common and serious events.

Common Side Effects: - Sedation or drowsiness. - Extrapyramidal symptoms such as parkinsonism or akathisia. - Dry mouth. - Constipation.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome, a life‑threatening reaction. - Tardive dyskinesia with long‑term use. - Severe hypotension. - Cardiac arrhythmias, including QT prolongation.

Before initiating bromperidol therapy, clinicians should consider several safety measures.

Monitor extrapyramidal symptoms: assess for movement disorders regularly. Assess cardiovascular status: watch for hypotension and ECG changes. Evaluate liver function: adjust if hepatic impairment is present. Use caution in elderly patients with dementia-related psychosis: increased mortality risk. Avoid abrupt discontinuation: taper to reduce withdrawal effects. Store at room temperature: keep in the original pack, protect from moisture.

Bromperidol can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - CNS depressants (e.g., alcohol, benzodiazepines): increased sedation. - Antihypertensives: additive hypotensive effect. - CYP2D6 inhibitors (e.g., fluoxetine): elevated bromperidol plasma levels.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may mask extrapyramidal symptoms. - QT‑prolonging drugs (e.g., erythromycin): heightened risk of cardiac arrhythmia.